SG11201907451XA - Substituted imidazo-quinolines as nlrp3 modulators - Google Patents

Substituted imidazo-quinolines as nlrp3 modulators

Info

Publication number
SG11201907451XA
SG11201907451XA SG11201907451XA SG11201907451XA SG11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA
Authority
SG
Singapore
Prior art keywords
princeton
route
line road
international
province line
Prior art date
Application number
SG11201907451XA
Other languages
English (en)
Inventor
Gary Glick
Shomir Ghosh
William R Roush
Edward James Olhava
Daniel O'malley
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61283434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907451X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of SG11201907451XA publication Critical patent/SG11201907451XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Transducers For Ultrasonic Waves (AREA)
SG11201907451XA 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators SG11201907451XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762460677P 2017-02-17 2017-02-17
US201762490881P 2017-04-27 2017-04-27
US201762573991P 2017-10-18 2017-10-18
PCT/US2018/018484 WO2018152396A1 (en) 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators

Publications (1)

Publication Number Publication Date
SG11201907451XA true SG11201907451XA (en) 2019-09-27

Family

ID=61283434

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907451XA SG11201907451XA (en) 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators

Country Status (29)

Country Link
US (4) US10533005B2 (hr)
EP (2) EP3510034B1 (hr)
JP (1) JP7003143B6 (hr)
KR (1) KR102329062B1 (hr)
CN (1) CN110325534B (hr)
AU (1) AU2018221076B2 (hr)
BR (1) BR112019016625A2 (hr)
CA (1) CA3053949A1 (hr)
CL (1) CL2019002324A1 (hr)
CO (1) CO2019008932A2 (hr)
CY (1) CY1123305T1 (hr)
DK (1) DK3510034T3 (hr)
ES (1) ES2799900T3 (hr)
HR (1) HRP20201087T1 (hr)
HU (1) HUE050965T2 (hr)
IL (1) IL268640B (hr)
LT (1) LT3510034T (hr)
ME (1) ME03801B (hr)
MX (1) MX2019009788A (hr)
MY (1) MY194054A (hr)
PE (1) PE20191552A1 (hr)
PL (1) PL3510034T3 (hr)
PT (1) PT3510034T (hr)
RS (1) RS60548B1 (hr)
SG (1) SG11201907451XA (hr)
SI (1) SI3510034T1 (hr)
TW (1) TWI674261B (hr)
WO (1) WO2018152396A1 (hr)
ZA (1) ZA201906104B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
AU2018301681B2 (en) 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
PT3658539T (pt) 2017-07-24 2024-04-26 Novartis Ag Compostos e composições para tratar condições associadas à atividade de nlrp
BR112020003014A2 (pt) 2017-08-15 2020-07-28 Inflazome Limited sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
RS62818B1 (sr) 2017-10-18 2022-02-28 Incyte Corp Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2020037091A1 (en) * 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
MX2021001581A (es) 2018-08-16 2021-04-19 Innate Tumor Immunity Inc Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
CN112996567A (zh) * 2018-08-16 2021-06-18 先天肿瘤免疫公司 咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂
CN111253390B (zh) * 2018-11-30 2023-10-03 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
JP2022517112A (ja) * 2019-01-14 2022-03-04 イネイト・テューマー・イミュニティ・インコーポレイテッド Nlrp3モジュレーター
WO2020150115A1 (en) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN113195469B (zh) 2019-02-19 2024-05-24 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023507322A (ja) * 2019-12-20 2023-02-22 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なToll様受容体(「TLR」)アゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
KR102409345B1 (ko) * 2020-09-22 2022-06-16 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
CN116874340B (zh) * 2023-07-10 2024-04-05 湖北航天化学技术研究所 一种苯基***类含能共晶化合物及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US948029A (en) * 1909-04-23 1910-02-01 James Harvey Leffler Reclining-chair.
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
DK0872478T3 (da) * 1991-03-01 2003-03-31 Minnesota Mining & Mfg Mellemprodukter til fremstilling af 1-substituerede, 2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004058759A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
KR101106812B1 (ko) 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007513170A (ja) 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007530579A (ja) * 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
BRPI0515316A (pt) 2004-09-14 2008-07-15 Chiron Corp compostos de imidazoquinolina
AU2005323024A1 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company Multi-route administration of immune response modifier compounds
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
WO2007079086A1 (en) * 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) * 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
CN107011441B (zh) 2013-09-13 2020-12-01 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
WO2015095780A1 (en) 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN112546231A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
CN108289912A (zh) 2015-09-01 2018-07-17 先天肿瘤免疫公司 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于***的抗-egfr组合
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2017132825A1 (zh) 2016-02-02 2017-08-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
BR112018071347A2 (pt) * 2016-04-19 2019-02-05 Innate Tumor Immunity Inc moduladores de nlrp3
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑

Also Published As

Publication number Publication date
IL268640B (en) 2021-12-01
US20200157096A1 (en) 2020-05-21
CY1123305T1 (el) 2021-12-31
DK3510034T3 (da) 2020-07-27
US10533005B2 (en) 2020-01-14
ZA201906104B (en) 2021-05-26
US20220289736A1 (en) 2022-09-15
AU2018221076B2 (en) 2020-12-24
AU2018221076A1 (en) 2019-10-03
CN110325534A (zh) 2019-10-11
PL3510034T3 (pl) 2020-11-30
TW201835077A (zh) 2018-10-01
ES2799900T3 (es) 2020-12-22
WO2018152396A1 (en) 2018-08-23
US20190055236A1 (en) 2019-02-21
US20240067649A1 (en) 2024-02-29
EP3753938B1 (en) 2024-03-20
RS60548B1 (sr) 2020-08-31
SI3510034T1 (sl) 2020-11-30
KR20190117657A (ko) 2019-10-16
LT3510034T (lt) 2020-08-10
IL268640A (en) 2019-10-31
MX2019009788A (es) 2019-10-07
EP3510034A1 (en) 2019-07-17
CL2019002324A1 (es) 2019-11-29
HUE050965T2 (hu) 2021-01-28
US11827632B2 (en) 2023-11-28
CN110325534B (zh) 2024-04-05
ME03801B (me) 2021-04-20
NZ757257A (en) 2021-11-26
JP7003143B2 (ja) 2022-01-20
JP2020508302A (ja) 2020-03-19
KR102329062B1 (ko) 2021-11-18
PE20191552A1 (es) 2019-10-24
JP7003143B6 (ja) 2024-02-26
BR112019016625A2 (pt) 2020-04-14
CA3053949A1 (en) 2018-08-23
PT3510034T (pt) 2020-06-23
TWI674261B (zh) 2019-10-11
MY194054A (en) 2022-11-10
HRP20201087T1 (hr) 2020-10-30
EP3753938A1 (en) 2020-12-23
EP3510034B1 (en) 2020-04-22
CO2019008932A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201809082WA (en) Nlrp3 modulators
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201906465YA (en) Tigit- and light-based chimeric proteins
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201901937WA (en) Pyridine compound
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809882XA (en) Pharmaceutical combinations for treating cancer